Literature DB >> 19617854

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

Alison Hamilton1, Christian Hölscher.   

Abstract

Glucagon-like-peptide-1 is an incretin hormone that also has neuroprotective properties. Here we analyse where glucagon-like-peptide-1 receptors are expressed in the brain. The receptor is found only on neurons, not on glia cells. The pyramidal cell layer of the CA region and the granule cell layer of the dentate gyrus in the hippocampus show intense staining. In the neocortex, larger pyramidal neurons express the receptor. In the cerebellum, only Purkinje neurons express the receptor. Dendrites of larger neurons were stained; in particular, pyramidal cells in area CA and dendrites of Purkinje cells. The fact that the receptor is located on neurons and dendrites suggests that the neuroprotective action is caused by the modulation of neuronal excitation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617854     DOI: 10.1097/WNR.0b013e32832fbf14

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  81 in total

1.  The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.

Authors:  Y Diz-Chaves; L Toba; J Fandiño; L C González-Matías; L M Garcia-Segura; F Mallo
Journal:  J Neuroinflammation       Date:  2018-12-05       Impact factor: 8.322

Review 2.  Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke.

Authors:  Vladimer Darsalia; Martin Larsson; David Nathanson; Thomas Klein; Thomas Nyström; Cesare Patrone
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

3.  Modulation of Glucagon-like Peptide-1 (GLP-1) Potency by Endocannabinoid-like Lipids Represents a Novel Mode of Regulating GLP-1 Receptor Signaling.

Authors:  Yu-Hong Cheng; Mei-Shang Ho; Wei-Ting Huang; Ying-Ting Chou; Klim King
Journal:  J Biol Chem       Date:  2015-04-22       Impact factor: 5.157

4.  Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

Authors:  Liqin Qi; Zhou Chen; Yanping Wang; Xiaoying Liu; Xiaohong Liu; Linfang Ke; Zhongjie Zheng; Xiaowei Lin; Yu Zhou; Lijuan Wu; Libin Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

5.  Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Authors:  Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Chaim G Pick; Nigel H Greig; Dong Seok Kim
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

6.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 7.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

8.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 9.  Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia.

Authors:  Hiroyuki Umegaki
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

Review 10.  Cerebral cortex: a target and source of insulin?

Authors:  Éva A Csajbók; Gábor Tamás
Journal:  Diabetologia       Date:  2016-05-20       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.